Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Feb 2, 2018 02:18PM Form SC 13D resTORbio, Inc. Filed by: ORBIMED ADVISORS LLC
Jan 30, 2018 06:41PM Form 4 ORBIMED ADVISORS LLC For: Jan 30 Filed by: resTORbio, Inc.
Jan 30, 2018 05:15PM Form 4 ORBIMED ADVISORS LLC For: Jan 30 Filed by: ARMO BioSciences, Inc.
Jan 30, 2018 04:31PM Form 4 ORBIMED ADVISORS LLC For: Jan 26 Filed by: SYNLOGIC, INC.
Jan 30, 2018 03:34PM Form 4 ORBIMED ADVISORS LLC For: Jan 26 Filed by: Kala Pharmaceuticals, Inc.
Jan 29, 2018 05:48PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Jan 29, 2018 05:38PM Form SC 13D/A Intellia Therapeutics, Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 05:29PM Form SC 13D/A SYNLOGIC, INC. Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 04:56PM Form SC 13D/A Verona Pharma plc Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 04:02PM Form SC 13D/A Sorrento Tech, Inc. Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 03:25PM Form SC 13D/A ViewRay, Inc. Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 03:16PM Form SC 13D/A SteadyMed Ltd. Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 03:09PM Form SC 13D/A SELECTA BIOSCIENCES INC Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 03:05PM Form SC 13D/A scPharmaceuticals Inc. Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 02:41PM Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 02:37PM Form SC 13D/A Adaptimmune Therapeutics Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 02:21PM Form SC 13D/A Arsanis, Inc. Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 12:23PM Form SC 13D/A ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 12:12PM Form SC 13D/A Nabriva Therapeutics Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 12:05PM Form SC 13D/A Clementia Pharmaceutical Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 11:51AM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 06:04AM Form SC 13D/A ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 06:04AM Form SC 13D/A Clementia Pharmaceutical Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 06:04AM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 06:04AM Form SC 13D/A Nabriva Therapeutics Filed by: ORBIMED ADVISORS LLC
Jan 25, 2018 08:51PM Form 3 resTORbio, Inc. For: Jan 25 Filed by: ORBIMED ADVISORS LLC
Jan 25, 2018 05:59PM Form 3 ORBIMED ADVISORS LLC For: Jan 25 Filed by: ARMO BioSciences, Inc.
Jan 24, 2018 09:00PM Form 4 Kala Pharmaceuticals, For: Jan 12 Filed by: ORBIMED ADVISORS LLC
Jan 23, 2018 10:00AM Skyhawk Therapeutics Launches With $8 Million in Seed Financing to Advance Its Novel Platform and Portfolio of Small Molecules That Correct RNA Expression
Jan 17, 2018 05:20PM Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
Jan 17, 2018 08:38AM PlacementTracker Publishes 2017 PIPE and Private Placement Markets League Tables
Jan 12, 2018 05:03PM Form SC 13G Kala Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Jan 5, 2018 03:15PM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jan 4, 2018 07:27AM Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept
Dec 20, 2017 08:30AM ORIC Has Appointed Rich Heyman, PhD as Acting Chief Executive Officer and Leonard Reyno, MD as Chief Medical Officer
Dec 13, 2017 07:30AM Pionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment
Dec 7, 2017 08:08PM OrbiMed Founder, Samuel D. Isaly, to Step Down
Dec 5, 2017 08:00AM PMV Pharma Appoints Winston Kung as COO & CFO
Dec 5, 2017 07:30AM Goldfinch Bio Appoints Anthony Johnson, M.D., President and Chief Executive Officer, and Michael Broxson, Chief Business and Operating Officer
Dec 1, 2017 12:40PM Form SC 13D scPharmaceuticals Inc. Filed by: ORBIMED ADVISORS LLC
Nov 30, 2017 02:51PM Form SC 13D Arsanis, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 20, 2017 04:28PM Form SC 13D/A Loxo Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 14, 2017 05:20PM Form 13F-HR ORBIMED ADVISORS LLC For: Sep 30
Nov 13, 2017 04:05PM Alpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial Results
Nov 8, 2017 04:05PM Natera Reports Third Quarter 2017 Financial Results
Nov 8, 2017 03:52PM Form SC 13D/A Intellia Therapeutics, Filed by: ORBIMED ADVISORS LLC
Nov 1, 2017 02:20PM Inspire Medical Systems Ranks #2 on Cleveland Clinic’s List of the Top 10 Medical Innovations for 2018
Oct 27, 2017 12:03PM Form SC 13D/A ViewRay, Inc. Filed by: ORBIMED ADVISORS LLC
Oct 27, 2017 08:35AM ORIC Pharmaceuticals Announces First Subject Dosed in Phase 1 Clinical Study of Novel GR Antagonist with Planned Development for Oncology
Oct 20, 2017 04:18PM Form SC 13D RHYTHM PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed